Dag Aarsland

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/628921/dag-aarsland-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

547
papers38,105
citations90
h-index184
g-index630
ext. papers46,437
ext. citations5.8
avg, IF7.33
L-index

#	Paper	IF	Citations
547	Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities <i>Nature Reviews Neurology</i> , 2022 ,	15	5
546	Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology Journal of Neurology, 2022 , 1	5.5	1
545	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum <i>JAMA Neurology</i> , 2022 ,	17.2	9
544	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts British Journal of Psychiatry, 2022 , 1-10	5.4	1
543	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data <i>Alzheimer Research and Therapy</i> , 2022 , 14, 14	9	O
542	Tongue muscle mass is associated with total grey matter and hippocampal volumes in Dementia with Lewy Bodies <i>Archives of Gerontology and Geriatrics</i> , 2022 , 100, 104647	4	
541	Actions to be taken for improving functional prognosis in dementia <i>Journal of the Neurological Sciences</i> , 2022 , 434, 120156	3.2	
540	The neuropsychiatry of Parkinson's disease: advances and challenges <i>Lancet Neurology, The</i> , 2022 , 21, 89-102	24.1	10
539	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts - ERRATUM <i>British Journal of Psychiatry</i> , 2022 , 1-2	5.4	
538	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography Journal of Neuropsychiatry and Clinical Neurosciences, 2022 , appineuropsych21050135	2.7	1
537	Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness <i>Dementia and Geriatric Cognitive Disorders</i> , 2022 , 1-10	2.6	O
536	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases <i>Neurobiology of Aging</i> , 2022 , 115, 88-108	5.6	0
535	New insights into the genetic etiology of Alzheimer's disease and related dementias <i>Nature Genetics</i> , 2022 ,	36.3	27
534	Specific depressive symptoms are related with different patterns of alcohol use in community-dwelling older adults <i>Archives of Gerontology and Geriatrics</i> , 2022 , 101, 104696	4	
533	Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report <i>Frontiers in Neurology</i> , 2022 , 13, 839539	4.1	2
532	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations <i>Translational Neurodegeneration</i> , 2022 , 11, 24	10.3	0
531	Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease <i>Health Science Reports</i> , 2022 , 5, e590	2.2	

(2021-2022)

530	Are subtypes of affective symptoms differentially associated with change in cognition over time: A latent class analysis <i>Journal of Affective Disorders</i> , 2022 , 309, 437-445	6.6	O
529	Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging. <i>Journal of Alzheimerg Disease</i> , 2022 , 1-11	4.3	3
528	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2021 , 152, 1052.	5 4 ·4	1
527	Risky drinking and cognitive impairment in community residents aged 50 and bver. <i>Aging and Mental Health</i> , 2021 , 1-8	3.5	1
526	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2021 ,	17.2	4
525	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. <i>Scientific Reports</i> , 2021 , 11, 20375	4.9	O
524	Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. <i>International Psychogeriatrics</i> , 2021 , 33, 505-514	3.4	48
523	The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1726-1737	4.6	2
522	Resting-state EEG alpha/theta ratio related to neuropsychological test performance in Parkinson's Disease. <i>Clinical Neurophysiology</i> , 2021 , 132, 756-764	4.3	4
521	Body mass index, performance on activities of daily living and cognition: analysis in two different populations. <i>BMC Geriatrics</i> , 2021 , 21, 177	4.1	1
520	Presynaptic accumulation of Bynuclein causes synaptopathy and progressive neurodegeneration in. <i>Brain Communications</i> , 2021 , 3, fcab049	4.5	2
519	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021 , 11, e02086	3.4	1
518	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. <i>Alzheimerg Research and Therapy</i> , 2021 , 13, 89	9	10
517	A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 1471-1487	3.9	3
516	Regression-based norms for the FAS phonemic fluency test for ages 40-84 based on a Norwegian sample. <i>Applied Neuropsychology Adult</i> , 2021 , 1-10	1.9	1
515	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
514	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	5
513	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51

512	Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies. <i>Frontiers in Neurology</i> , 2021 , 12, 679984	4.1	O
511	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 47	51.1	55
510	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	5
509	Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2021 , 268, 2769-2779	5.5	12
508	The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. <i>Multivariate Behavioral Research</i> , 2021 , 56, 70-85	2.3	2
507	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021 , 36, 89-101	12.1	8
506	The association between aspects of carer distress and time until nursing home admission in persons with Alzheimer's disease and dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2021 , 33, 337-345	3.4	6
505	Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 573-584	6.5	O
504	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 299-307	5.3	6
503	Mild cognitive impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021 , 50, 72-80	3	20
503	Mild cognitive impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021 , 50, 72-80 Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021 , 146, 111223	3 4·5	20
	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> ,		
502	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021 , 146, 111223 Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal</i>	4.5	
502	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021 , 146, 111223 Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1162-1174 An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). <i>Alzheimerg and Dementia: Translational Research and Clinical</i>	4·5 7·3	2
502 501 500	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021 , 146, 111223 Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1162-1174 An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). <i>Alzheimer</i> and <i>Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12171 Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older	4·5 7·3	2 4 3
502 501 500 499	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021 , 146, 111223 Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1162-1174 An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12171 Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. <i>Alzheimers and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12164 Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. <i>Alzheimers and Dementia: Diagnosis</i> ,	4·5 7·3 6	2 4 3
502 501 500 499 498	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021, 146, 111223 Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1162-1174 An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). <i>Alzheimerg and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12171 Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. <i>Alzheimerg and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12164 Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. <i>Alzheimerg and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12235 Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer's	4·5 7·3 6 5·2 5·2	2 4 3 12

494	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31
493	Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia. <i>Frontiers in Psychiatry</i> , 2021 , 12, 706695	5	5
492	Muscle volume and intramuscular fat of the tongue evaluated with MRI predict malnutrition in people living with dementia: a five-year follow-up study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 ,	6.4	2
491	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer& Disease</i> , 2021 , 82, 913-919	4.3	5
490	Serum tyrosine is associated with better cognition in Lewy body dementia. <i>Brain Research</i> , 2021 , 1765, 147481	3.7	O
489	Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia. <i>International Psychogeriatrics</i> , 2021 , 33, 1217-1228	3.4	2
488	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinsong Disease</i> , 2021 , 11, 1209-1219	5.3	8
487	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer's Disease. Journal of Alzheimer Disease, 2021 , 83, 1825-1839	4.3	2
486	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021 , 53, 1276-1282	36.3	40
485	Polypharmacy is associated with functional decline in Alzheimer's disease and Lewy body dementia. <i>Archives of Gerontology and Geriatrics</i> , 2021 , 96, 104459	4	5
484	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021 , 105, 252-261	5.6	2
483	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021 , 106, 304.e1-304.e3	5.6	1
482	Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia. <i>Alzheimers and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12152	5.2	1
481	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer</i> and Dementia, 2021 , 17, 1145-1156	1.2	48
480	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. <i>Frontiers in Psychiatry</i> , 2020 , 11, 602480	5	
479	Cleaved Annexin A1 is elevated in neurodegenerative dementia and is associated with pathological burden of amyloid and inflammatory cytokines. <i>Alzheimerg</i> and Dementia, 2020 , 16, e037636	1.2	
478	Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes. <i>Alzheimerg and Dementia</i> , 2020 , 16, e039139	1.2	1
477	Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>Alzheimerg and Dementia</i> , 2020 , 16, e039145	1.2	

476	Clinical factors associated with progression to dementia in people with late-life depression: A cohort study of patients in secondary care. <i>Alzheimerg and Dementia</i> , 2020 , 16, e039147	1.2	
475	Decreased JNK3 levels are associated with amyloid plaque and neurofibrillary tangles in dementia patients. <i>Alzheimerg and Dementia</i> , 2020 , 16, e039231	1.2	
474	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer disease in the absence of AT(N) classification as the reference standard. <i>Alzheimer and Dementia</i> , 2020 , 16, e041	8 0 8	0
473	Neuropsychiatric symptoms correlated with functional trajectories among people living with Alzheimer disease dementia and Lewy body dementia. <i>Alzheimer and Dementia</i> , 2020 , 16, e041881	1.2	
472	The ANeED study: Ambroxol in new and early dementia with Lewy bodies. <i>Alzheimerg</i> and Dementia , 2020 , 16, e042589	1.2	1
471	A systematic review on the physical and mental health risk factors of mild cognitive impairment and Alzheimer disease in military veterans. <i>Alzheimer and Dementia</i> , 2020 , 16, e042913	1.2	
470	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimerg and Dementia</i> , 2020 , 16, e043593	1.2	
469	A prospective long-term study of TDP-43 pathology in Alzheimer disease aggression. <i>Alzheimer and Dementia</i> , 2020 , 16, e043659	1.2	
468	Neuropsychiatric symptoms and cognitive decline: Trait or state effects?. <i>Alzheimerg</i> and Dementia, 2020 , 16, e043789	1.2	
467	Functional alterations in visual networks underlie differences in the phenomenology of visual hallucinations in Lewy body disease. <i>Alzheimerg and Dementia</i> , 2020 , 16, e045102	1.2	
466	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson and Lewy body diseases. <i>Alzheimers and Dementia</i> , 2020 , 16, e045811	1.2	
465	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson and Lewy body diseases. <i>Alzheimerg and Dementia</i> , 2020 , 16, e045886	1.2	1
464	Plasma-based biomarkers for Aland tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer disease. <i>Alzheimer and Dementia</i> , 2020 , 16, e046490	1.2	
463	Plasma p-tau181 accurately predicts Alzheimer disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer and Dementia</i> , 2020 , 16, e047539	1.2	2
462	The reliability of a deep learning model in external memory clinic MRI data: A multi-cohort study. <i>Alzheimer</i> and <i>Dementia</i> , 2020 , 16, e042969	1.2	
461	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimerg. and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12098	5.2	1
460	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745	4.9	10
459	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020 , 66, 101714	15.4	26

(2020-2020)

458	Mental health of people living with dementia in care homes during COVID-19 pandemic. <i>International Psychogeriatrics</i> , 2020 , 32, 1253-1254	3.4	27	
457	Clinical factors associated with progression to dementia in people with late-life depression: a cohort study of patients in secondary care. <i>BMJ Open</i> , 2020 , 10, e035147	3	3	
456	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020 , 91, 88-111	5.6	13	
455	Temporal Relationship Between Depressive Symptoms and Cognition in Mid and Late Life: A Longitudinal Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 1108-1113	5.9	6	
454	Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer's Disease. <i>Brain Sciences</i> , 2020 , 10,	3.4	2	
453	Colombian consortium for the study of Lewy body dementia COL-DLB. <i>Journal of the Neurological Sciences</i> , 2020 , 412, 116807	3.2	1	
452	Risk of Hospitalization in Patients with Alzheimer's Disease and Lewy Body Dementia: Time to and Length of Stay. <i>Journal of Alzheimer Disease</i> , 2020 , 74, 1221-1230	4.3	1	
451	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 265-284	15	53	
45°	Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia. <i>Neuropsychology</i> , 2020 , 34, 851-861	3.8	1	
449	Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer</i> Disease, 2020 , 77, 1117-1127	4.3	1	
448	Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. <i>Programme Grants for Applied Research</i> , 2020 , 8, 1-98	1.5	6	
447	Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2020 , 26, 803-818	11.5	30	
446	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 32-36	2.2	8	
445	Components of the choline oxidation pathway modify the association between the apolipoprotein gene variant and cognitive decline in patients with dementia. <i>Brain Research</i> , 2020 , 1726, 146519	3.7	2	
444	Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. Journal of Alzheimer Disease, 2020, 73, 1321-1330	4.3	6	
443	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020 , 35, 595-605	7	19	
442	EAmyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020 , 95, e3257-e3268	6.5	18	
441	Hippocampal subfields and decline in activities of daily living in Alzheimer's disease and dementia with Lewy bodies. <i>Neurodegenerative Disease Management</i> , 2020 , 10, 357-367	2.8	3	

440	Psychosis in Alzheimer's Disease. Current Neurology and Neuroscience Reports, 2020, 20, 57	6.6	10
439	The combined effect of amyloid-hand tau biomarkers on brain atrophy in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020 , 27, 102333	5.3	9
438	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimerg Research and Therapy</i> , 2020 , 12, 153	9	2
437	Selecting Remote Measurement Technologies to Optimize Assessment of Function in Early Alzheimer's Disease: A Case Study. <i>Frontiers in Psychiatry</i> , 2020 , 11, 582207	5	4
436	Systems Biology Approaches to Understand the Host-Microbiome Interactions in Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020 , 14, 716	5.1	20
435	Psychiatric and neuropsychiatric syndromes and COVID-19. Lancet Psychiatry, the, 2020, 7, 663-664	23.3	2
434	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8Dyears prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020 , 140, 267-278	14.3	79
433	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. <i>Neurobiology of Aging</i> , 2020 , 95, 26-45	5.6	17
432	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 2257-2263	5.6	11
431	Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020 , 9, 36	10.3	15
430	Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2020 , 11, 916	4.1	O
429	Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. <i>Frontiers in Psychiatry</i> , 2020 , 11, 579934	5	23
428	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020 , 16, 661-673	315	44
427	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer Disease</i> , 2020 , 77, 1143-1155	4.3	5
426	Trajectories of depressive symptoms and associated patterns of cognitive decline. <i>Scientific Reports</i> , 2020 , 10, 20888	4.9	12
425	Mediating effect of mutuality on caregiver burden in Parkinson's disease partners. <i>Aging and Mental Health</i> , 2020 , 24, 1421-1428	3.5	11
424	Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020 , 32, 705-717	3.4	37
423	CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 109-110	5.5	4

422	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 75-86	6.5	17
421	The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. <i>British Journal of Psychiatry</i> , 2020 , 216, 43-48	5.4	33
420	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 449-461	5.3	18
419	Association between physical activity and cognition in Mexican and Korean older adults. <i>Archives of Gerontology and Geriatrics</i> , 2020 , 89, 104047	4	4
418	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020 , 94, 743-7	75 555	151
417	The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism. <i>Autism Research</i> , 2020 , 13, 641-654	5.1	4
416	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 5	7.3	79
415	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 823-834	6.5	85
414	Prevalence of late-life depression and gap in mental health service use across European regions. <i>European Psychiatry</i> , 2019 , 57, 19-25	6	48
413	Frailty in Older Adults with Mild Dementia: Dementia with Lewy Bodies and Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019 , 9, 176-183	2.5	17
412	GBA and APOE A associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019 , 9, 7013	4.9	24
411	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinsong Disease</i> , 2019 , 5, 7	9.7	24
410	The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 1421-1428	3.9	5
409	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 202-210	3.6	19
408	ASSOCIATION OF DEPRESSIVE SYMPTOMS AND SUBJECTIVE MEMORY COMPLAINTS WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER ADULTS WITH HIGH BLOOD PRESSURE. European Geriatric Medicine, 2019 , 10, 413-420	3	12
407	Glial activation and inflammation along the Alzheimer's disease continuum. <i>Journal of Neuroinflammation</i> , 2019 , 16, 46	10.1	97
406	Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. Journal of Alzheimerg Disease, 2019, 68, 239-253	4.3	1
405	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019 , 85, 715-725	9.4	27

404	Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways. <i>CNS Drugs</i> , 2019 , 33, 143-160	6.7	14
403	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019 , 5, eaau7220	14.3	44
402	Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. <i>Journal of Neural Transmission</i> , 2019 , 126, 327-337	4.3	12
401	Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies. <i>Journal of Alzheimerg Disease</i> , 2019 , 67, 995-1005	4.3	8
400	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <i>Brain Pathology</i> , 2019 , 29, 63-74	6	27
399	Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 728-730	5.5	9
398	Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia - A Pilot Study. <i>Frontiers in Genetics</i> , 2019 , 10, 536	4.5	8
397	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. <i>Translational Psychiatry</i> , 2019 , 9, 273	8.6	18
396	Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia. <i>International Journal of Tryptophan Research</i> , 2019 , 12, 1178646919877883	5.6	8
395	The relationship between the frequency of number-puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 932-940	3.9	4
394	Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease. <i>Scientific Reports</i> , 2019 , 9, 17222	4.9	6
393	Commentary: A posterior-to-anterior shift of brain functional dynamics in aging. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 341	5.3	1
392	The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein Allele Variant in Patients With Dementia. <i>International Journal of Tryptophan Research</i> , 2019 , 12, 1178646919885637	5.6	
391	The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 604-609	5.9	15
390	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimerg</i> and <i>Dementia</i> , 2019 , 15, 400-409	1.2	36
389	Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. <i>Ageing Research Reviews</i> , 2019 , 50, 72-80	12	32
388	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. <i>Nature Genetics</i> , 2019 , 51, 404-413	36.3	771
387	The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 330-339	5.9	31

(2018-2019)

386	In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. <i>Journal of Alzheimer</i> Disease, 2019, 67, 715-723	4.3	5
385	Amyloid-land Parkinson's disease. <i>Journal of Neurology</i> , 2019 , 266, 2605-2619	5.5	35
384	Investigating the relationship between age of onset of depressive disorder and cognitive function. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 38-46	3.9	12
383	Reduced Walking Speed in Subjective and Mild Cognitive Impairment: A Cross-Sectional Study. Journal of Geriatric Physical Therapy, 2019 , 42, E122-E128	3.2	10
382	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 247-268	4.3	30
381	Risk factors for non-motor symptoms in Parkinson's disease. <i>Lancet Neurology, The</i> , 2018 , 17, 559-568	24.1	108
380	Patterns of carer distress over time in mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 987-993	3.9	9
379	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018 , 33, 520-527	7	10
378	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018 , 33, 528-536	7	16
377	Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. <i>Alzheimers and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 143-152	5.2	29
376	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2018 , 65, 18-40	5.6	30
375	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018 , 141, 582-595	11.2	100
374	Prevalence of the apolipoprotein E A allele in amyloid positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer</i> and Dementia, 2018 , 14, 913-924	1.2	36
373	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. <i>American Journal of Medical Genetics Part B:</i> Neuropsychiatric Genetics, 2018 , 177, 232-241	3.5	28
372	Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. <i>International Psychogeriatrics</i> , 2018 , 30, 395-407	3.4	23
371	A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 124	4.1	7
370	Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1361-1369	3.9	43
369	Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2018 , 32, 621-635	6.7	21

368	Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, 761-774	4.3	6
367	Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). <i>Drugs and Aging</i> , 2018 , 35, 545-558	4.7	17
366	Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. <i>Alzheimerg Research and Therapy</i> , 2018 , 10, 83	9	10
365	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018 , 13, e0201964	3.7	21
364	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018 , 15, 883-891	3	11
363	Association of Cerebral Amyloid-Daggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
362	P3-243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY 2018 , 14, P1165-P1166		
361	P3-554: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATION-BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY 2018 , 14, P1335-P1335		2
360	P1-523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBI-C) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS 2018 , 14, P532-P532		
359	P1-151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE 2018 , 14, P335-P335		
358	P2-483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER 2018 , 14, P914-P914		
357	P1-658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS 2018 , 14, P595-P595		1
356	O1-10-04: ABNORMALITIES OF RESTING STATE FUNCTIONAL CORTICAL CONNECTIVITY IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S AND LEWY BODY DISEASES: AN EEG STUDY 2018 , 14, P244-P245		
355	Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci. <i>Scientific Reports</i> , 2018 , 8, 18088	4.9	25
354	Cognitive Interventions in Parkinson's Disease: Where We Want to Go within 20 Years. <i>Journal of Parkinsong Disease</i> , 2018 , 8, S107-S113	5.3	15
353	Cerebrospinal fluid neurogranin/Bite APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer</i> and Dementia: Translational Research and Clinical Interventions, 2018 , 4, 617-627	6	17
352	Mediating Effect of Mutuality on Health-Related Quality of Life in Patients with Parkinson's Disease. <i>Parkinson Disease</i> , 2018 , 2018, 9548681	2.6	4
351	P3-001: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA 2018 , 14, P1062-P1062		

(2017-2018)

350	Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). <i>Clinical Interventions in Aging</i> , 2018 , 13, 935-946	4	24
349	Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 183-192	3.9	19
348	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 81-95	15	165
347	Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia. <i>Journal of Alzheimer Disease</i> , 2017 , 56, 575-584	4.3	15
346	SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics. <i>Scientific Reports</i> , 2017 , 7, 41929	4.9	18
345	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimer& Disease</i> , 2017 , 57, 373-386	4.3	13
344	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 217-231	15	458
343	Lewy Body Dementias. Focus (American Psychiatric Publishing), 2017, 15, 85-100	1.1	1
342	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2017 , 55, 143-158	5.6	46
341	Associations between pain and depression in nursing home patients at different stages of dementia. <i>Journal of Affective Disorders</i> , 2017 , 218, 8-14	6.6	31
340	A new tool to identify patients with Parkinson's disease at increased risk of dementia. <i>Lancet Neurology, The</i> , 2017 , 16, 576-578	24.1	3
339	Psychosis in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 585-622	4.4	22
338	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
337	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimers Disease</i> , 2017 , 57, 387-393	4.3	8
336	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimerg. Disease</i> , 2017 , 57, 787-795	4.3	54
335	The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 703-717	3.9	58
334	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 325-331	5.5	51
333	The prognosis of dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2017 , 16, 390-398	24.1	116

332	Increased Transforming Growth Factor II in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble AII Load. <i>Journal of Alzheimerg Disease</i> , 2017 , 56, 157-166	4.3	17
331	Cognitive Deficits in Chronic Stroke Patients: Neuropsychological Assessment, Depression, and Self-Reports. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017 , 7, 283-296	2.5	30
330	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. <i>Journal of Alzheimerg Disease</i> , 2017 , 59, 339-358	4.3	26
329	[P3 0 17]: HEADWAY-DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES 2017 , 13, P936		4
328	Detecting At-Risk Alzheimer's Disease Cases. Journal of Alzheimer Disease, 2017, 60, 97-105	4.3	23
327	Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. <i>Journal of Alzheimerg Disease</i> , 2017 , 59, 929-939	4.3	7
326	Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. <i>Npj Genomic Medicine</i> , 2017 , 2, 24	6.2	8
325	Impaired synaptic function is linked to cognition in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 700-713	5.3	15
324	Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 132, 275-294	4.4	21
323	Synaptic proteins in CSF relate to Parkinson's disease stage markers. <i>Npj Parkinson Disease</i> , 2017 , 3, 7	9.7	30
322	Psychometric properties of the mutuality scale in Swedish dyads with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 122-128	3.8	8
321	Classifying Alzheimer's disease, Lewy body dementia, and normal controls using 3D texture analysis in magnetic resonance images. <i>Biomedical Signal Processing and Control</i> , 2017 , 33, 19-29	4.9	8
320	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017 , 44, 283-293	2.6	6
319	[P1235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUB-UNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS 2017 , 13, P333-P334		
318	[P3043]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY 2017 , 13, P1033-P1033		
317	[P4🛮54]: DETECTING AT-RISK CASES FOR ALZHEIMER's DISEASE 2017 , 13, P1317-P1317		
316	[P1099]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE 2017 , 13, P367-P367		1
315	[P1월56]: INCREASED PSER129 SYNUCLEIN IS ASSOCIATED WITH SYNAPTIC DEFICITS IN DEMENTIA WITH LEWY BODIES 2017 , 13, P461-P461		

[P1B64]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES 2017, 13, P510-P511 1 314 [P2Ø04]: RPT6, 20S ₺ AND ₺ PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH 313 COGNITIVE DECLINE IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS 2017, 13, P684-P684 [F50103]: CLINICO-PATHOLOGIC ASSOCIATIONS IN DLB: RELEVANCE FOR DIAGNOSIS AND 312 TREATMENT 2017, 13, P1444-P1445 Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. Journal of 311 4.3 52 Alzheimer& Disease, **2017**, 59, 1139-1152 Screening for Alzheimer's Disease: Cognitive Impairment in Self-Referred and Memory 6 310 4.3 Clinic-Referred Patients. Journal of Alzheimer Disease, 2017, 60, 1621-1631 New Therapeutic Strategies for Lewy Body Dementias. Current Neurology and Neuroscience Reports, 6.6 309 23 **2017**, 17, 68 MRI-Based Classification Models in Prediction of Mild Cognitive Impairment and Dementia in 308 5.3 42 Late-Life Depression. Frontiers in Aging Neuroscience, 2017, 9, 13 REM Sleep Behavior Disorder Is Not Associated with a More Rapid Cognitive Decline in Mild 307 4.1 Dementia. Frontiers in Neurology, 2017, 8, 375 Determinants of Dyadic Relationship and Its Psychosocial Impact in Patients with Parkinson's 306 2.6 9 Disease and Their Spouses. Parkinsong Disease, 2017, 2017, 4697052 Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo 84 305 3.7 Parkinson disease. *PLoS ONE*, **2017**, 12, e0175674 The Lewy Body Dementias: Dementia with Lewy Bodies and Related Syndromes 2017, 211-224 304 Montreal Cognitive Assessment in a 63- to 65-year-old Norwegian Cohort from the General Population: Data from the Akershus Cardiac Examination 1950 Study. Dementia and Geriatric 303 2.5 9 Cognitive Disorders Extra, 2017, 7, 318-327 Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology, 2016, 6.5 302 14 87, 1045-51 Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: 301 4.3 50 Results from a Large Multicenter Cohort. Journal of Alzheimerg. Disease, 2016, 54, 287-95 Higher Frequency and Complexity of Sleep Disturbances in Dementia with Lewy Bodies as 300 2.3 29 Compared to Alzheimer's Disease. Neurodegenerative Diseases, 2016, 16, 152-60 Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early 16 299 9.7 Parkinson's disease: a cross-sectional study. Npj Parkinson Disease, 2016, 2, 15030 Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid 298 4.3 11 Markers. Journal of Alzheimerg Disease, 2016, 53, 621-30 Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's 6 297 4.3 Disease. Journal of Alzheimer Disease, 2016, 53, 349-61

296	Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2016 , 31, 1075-83	3.9	84
295	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. <i>Neurobiology of Aging</i> , 2016 , 42, 124-31	5.6	23
294	A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer's disease. <i>Alzheimer Research and Therapy</i> , 2016 , 8, 3	9	26
293	Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend analyses of four data samples. <i>Age and Ageing</i> , 2016 , 45, 54-60	3	46
292	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016 , 139 Suppl 1, 290-317	6	45
291	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016 , 123, 431-8	4.3	76
290	Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S144-8	3.6	85
289	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. Journal of Alzheimer Disease, 2016, 50, 101-10	4.3	18
288	Isoelectric point region pla.4 as a treasure island of abnormal proteoforms in blood. <i>Discoveries</i> , 2016 , 4, e67	3.7	3
287	Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. <i>Journal of Parkinson's Disease</i> , 2016 , 6, 413-21	5.3	9
286	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. <i>Movement Disorders</i> , 2016 , 31, 1203-8	7	50
285	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016 , 42, 352-65	5.2	32
284	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson Disease</i> , 2016 , 6, 733-739	5.3	3
283	Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. <i>BMJ Open</i> , 2016 , 6, e010357	3	41
282	Association of Butyrylcholinesterase-K Allele and Apolipoprotein E e4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 567-76	4.3	12
281	EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study. <i>Journal of Alzheimerg Disease</i> , 2016 , 54, 1649-1657	4.3	36
280	O3-04-02: Clinico-Pathologic Correlations in Dementia with Lewy Bodies (DLB): A Prospective Cohort Study 2016 , 12, P291-P291		
279	Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism. <i>Journal of Alzheimerg Disease</i> , 2016 , 53, 1277-85	4.3	10

(2015-2016)

278	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer and Dementia</i> , 2016 , 12, 1149-1158	1.2	86
277	Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 464.e1-7	5.9	11
276	Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. <i>Acta Psychiatrica Scandinavica</i> , 2016 , 134, 430-440	6.5	28
275	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with Eamyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016 , 9, 84	4.5	20
274	Signs of Imminent Dying and Change in Symptom Intensity During Pharmacological Treatment in Dying Nursing Home Patients: A Prospective Trajectory Study. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 821-7	5.9	16
273	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016 , 1862, 2110-2118	6.9	22
272	Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2016 , 31, 118-25	7	22
271	Medial temporal lobe atrophy and depressive symptoms in elderly patients with and without Alzheimer disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015 , 28, 40-8	3.8	14
270	Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. <i>Molecular Psychiatry</i> , 2015 , 20, 1588-95	15.1	107
269	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. <i>Neuroscience Letters</i> , 2015 , 594, 137-43	3.3	10
268	Amyloid-Land Esynuclein cerebrospinal fluid biomarkers and Lognition in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 758-64	3.6	41
267	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
266	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015 , 47, 445-7	36.3	222
265	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. <i>Human Brain Mapping</i> , 2015 , 36, 2980-95	5.9	67
264	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 919-27	7	179
263	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. <i>Circulation</i> , 2015 , 131, 2061-2069	16.7	100
262	Lewy body dementias. <i>Lancet, The</i> , 2015 , 386, 1683-97	40	303
261	Neuroanatomical correlates of late-life depression and associated cognitive changes. <i>Neurobiology of Aging</i> , 2015 , 36, 3090-3099	5.6	26

260	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015 , 11, 41-55	15	116
259	Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 46-54	3.9	49
258	Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 141-8	6.5	30
257	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015 , 25, 401-8	6	115
256	P2-135: CSF all 2 is related to cortical metabolism (FDG-PET) in non-demented parkinson's disease patients 2015 , 11, P536-P537		
255	Neuropsychiatric Symptoms in Parkinson's Disease. <i>Journal of Parkinson</i> Disease, 2015 , 5, 659-67	5.3	51
254	Harnessing the power of cohort studies for dementia research. <i>Journal of Public Mental Health</i> , 2015 , 14, 8-17	0.7	4
253	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinson Disease</i> , 2015 , 5, 783-92	5.3	31
252	Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease. <i>Journal of Alzheimer Disease</i> , 2015 , 47, 523-9	4.3	17
251	Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al. <i>Movement Disorders</i> , 2015 , 30, 1711	7	
250	Personality changes after deep brain stimulation in Parkinson's disease. <i>Parkinson Disease</i> , 2015 , 2015, 490507	2.6	28
249	Classifying dementia using local binary patterns from different regions in magnetic resonance images. <i>International Journal of Biomedical Imaging</i> , 2015 , 2015, 572567	5.2	23
248	COSMOSimproving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial. <i>Implementation Science</i> , 2015 , 10, 131	8.4	38
247	O5-03-04: Clinical characteristics and course of dlb: Results from a large longitudinal multicentre cohort 2015 , 11, P320-P320		2
246	Clinical and Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015 , 5, 212-20	2.5	23
245	Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 131, 139-47	6.5	18
244	A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 31	5.9 6-22	18
243	Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 321	-315	50

242	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014 , 29, 651-62	7	37
241	Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 392-8	3.9	69
240	Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: an MRI surface-based morphometric study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 4-13.e1	6.5	29
239	Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. <i>European Journal of Pain</i> , 2014 , 18, 1490-500	3.7	61
238	Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 930-5	5.5	34
237	The importance of pain management in older people with dementia. <i>British Medical Bulletin</i> , 2014 , 111, 139-48	5.4	67
236	Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 580-6	6.5	13
235	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimers and Dementia</i> , 2014 , 10, 713-723.e2	1.2	204
234	The use and costs of formal care in newly diagnosed dementia: a three-year prospective follow-up study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 381-8	6.5	41
233	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. <i>Neurology</i> , 2014 , 82, 2017-25	6.5	122
232	The response of agitated behavior to pain management in persons with dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 708-17	6.5	106
231	Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 335-43	2.5	25
230	Persistence and Prognostic Implications of Orthostatic Hypotension in Older Individuals with Mild-to-Moderate Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 283-96	2.5	3
229	A 5-YEAR LONGITUDINAL STUDY OF PATIENTS WITH DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE 2014 , 10, P261-P261		1
228	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review [] CORRIGENDUM. <i>International Psychogeriatrics</i> , 2014 , 26, 1099-1099	3.4	2
227	Grey matter changes in cognitively impaired Parkinson's disease patients. <i>PLoS ONE</i> , 2014 , 9, e85595	3.7	49
226	Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. <i>Frontiers in Systems Neuroscience</i> , 2014 , 8, 45	3.5	69
225	Neuropsychiatric symptoms in dementia-a role for neuroinflammation?. <i>Brain Research Bulletin</i> , 2014 , 108, 88-93	3.9	32

224	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. <i>International Psychogeriatrics</i> , 2014 , 26, 1083-98	3.4	109
223	Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. <i>BMJ Open</i> , 2014 , 4, e005158	3	38
222	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease. <i>Alzheimerg Research and Therapy</i> , 2014 , 6, 53	9	18
221	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. <i>NeuroImage: Clinical</i> , 2014 , 6, 115-25	5.3	158
220	Apolipoprotein E 🛭 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1227-31	5.5	47
219	White matter integrity and cognition in Parkinson's disease: a cross-sectional study. <i>BMJ Open</i> , 2014 , 4, e003976	3	31
218	Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. <i>Journal of Internal Medicine</i> , 2014 , 275, 317-30	10.8	54
217	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014 , 35, 2836-2844	5.6	74
216	Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 828-36	3.9	58
215	Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1802-8	7	55
214	Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. <i>Alzheimergs Research and Therapy</i> , 2014 , 6, 65	9	20
213	Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1809-15	7	62
212	Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 234-44	2.6	11
211	Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 161-9	2.6	42
210	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014 , 121, 71-8	4.3	3
209	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer s disease. <i>Alzheimer Research and Therapy</i> , 2014 , 6, 53	9	17
208	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014 , 3, 108	3.6	12
207	Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. <i>Journal of Neurology</i> , 2013 , 260, 1104-15	5.5	34

206	O3🛮 0 🗗 1: Clinical course of Lewy-body disease: Cognitive decline and mortality 2013 , 9, P537-P538		1
205	Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. <i>Drugs and Aging</i> , 2013 , 30, 603-1	1 ^{4.7}	36
204	(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. <i>BMJ Open</i> , 2013 , 3,	3	20
203	Cerebrospinal fluid amyloid-hand phenotypic heterogeneity in de novo Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013 , 84, 537-43	5.5	48
202	Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013 , 3, 281-90	2.5	7
201	Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013 , 3, 291-300	2.5	33
200	Mapping cortical atrophy in Parkinson's disease patients with dementia. <i>Journal of Parkinsong Disease</i> , 2013 , 3, 69-76	5.3	32
199	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2013, 3, 105-107	2.8	
198	Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. <i>Journal of Alzheimerg Disease</i> , 2013 , 33, 723-36	4.3	80
197	Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 927-35	3.1	24
196	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012 , 27, 349-56	7	1373
195	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012 , 379, 528-36	40	116
194	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurology, The, 2012 , 11, 697-707	24.1	342
193	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012 , 259, 1639-47	5.5	153
192	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012 , 531, 1-4	3.3	5
191	Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 34, 44-50	2.6	33
190	Assessment and treatment of pain in people with dementia. <i>Nature Reviews Neurology</i> , 2012 , 8, 264-74	15	207
189	Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines. <i>Journal of the Neurological Sciences</i> , 2012 , 322, 211-6	3.2	33

188	The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. <i>PLoS ONE</i> , 2012 , 7, e45451	3.7	84
187	Relationship between orthostatic hypotension and white matter hyperintensity load in older patients with mild dementia. <i>PLoS ONE</i> , 2012 , 7, e52196	3.7	9
186	Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012 , 2, 48-56	2.5	38
185	Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. <i>Current Neurology and Neuroscience Reports</i> , 2012 , 12, 492-501	6.6	35
184	Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 617-26	7	339
183	Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. International Journal of Geriatric Psychiatry, 2012, 27, 573-82	3.9	16
182	Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 628-36	3.9	64
181	Neuropsychiatric symptoms in mild dementia with lewy bodies and Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 34, 1-6	2.6	51
180	A pilot study examining associations between DYRK1A and Bynuclein dementias. <i>Neurodegenerative Diseases</i> , 2012 , 10, 229-31	2.3	16
179	White matter hyperintensities and the course of depressive symptoms in elderly people with mild dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012 , 2, 97-111	2.5	26
178	The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. <i>International Psychogeriatrics</i> , 2012 , 24, 1771-8	3.4	38
177	Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. <i>PLoS ONE</i> , 2012 , 7, e37410	3.7	160
176	Depression in Parkinson diseaseepidemiology, mechanisms and management. <i>Nature Reviews Neurology</i> , 2011 , 8, 35-47	15	338
175	Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. <i>BMJ, The</i> , 2011 , 343, d4065	5.9	371
174	Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 227-34	2.6	34
173	A novel blood test for the early detection of Alzheimer's disease. <i>Journal of Alzheimerg Disease</i> , 2011 , 23, 121-9	4.3	56
172	Cognitive and psychiatric disturbances in Parkinson disease. Aging Health, 2011, 7, 123-142		5
171	Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 621-4	3.6	47

(2011-2011)

170	Executive dysfunction in mild cognitive impairment is associated with changes in frontal and cingulate white matter tracts. <i>Journal of Alzheimerg Disease</i> , 2011 , 27, 453-62	4.3	48
169	Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. <i>CNS Neuroscience and Therapeutics</i> , 2011 , 17, 428-41	6.8	46
168	Alzheimer's disease. <i>Lancet, The</i> , 2011 , 377, 1019-31	40	1645
167	Cerebrospinal Fluid Levels of sAPPland sAPPlan Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimers Disease</i> , 2011 , 2011, 495025	3.7	16
166	Nonmotor symptoms of Parkinson's disease. <i>Parkinsong Disease</i> , 2011 , 2011, 351461	2.6	1
165	Journal Wach: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2011, 1, 187-189	2.8	
164	Mania after administration of cholinesterase inhibitors in patients with dementia and comorbid bipolar disorder: two case reports. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 254-6	1.7	11
163	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. <i>Neuropsychology</i> , 2011 , 25, 114-24	3.8	71
162	Depression in dementia: epidemiology, mechanisms, and treatment. <i>Current Opinion in Psychiatry</i> , 2011 , 24, 461-72	4.9	198
161	Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. <i>Acta Psychiatrica Scandinavica</i> , 2011 , 123, 459-65	6.5	26
160	Identification of novel Bynuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. <i>Neurochemical Research</i> , 2011 , 36, 2029-42	4.6	74
159	Mild cognitive impairment in Parkinson's disease. <i>Current Neurology and Neuroscience Reports</i> , 2011 , 11, 371-8	6.6	100
158	Reply: Neuropsychiatric symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 191-192	7	
157	Nonlinear decline of mini-mental state examination in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 334-7	7	36
156	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 297-301	7	43
155	Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 824-9	7	24
154	The economic impact of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 15	4] -4	74
153	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , 2011 , 26, 1814-24	7	527

152	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2483-95	7	95
151	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 206-13	3.9	18
150	Hypertension is a potential risk factor for vascular dementia: systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 661-9	3.9	137
149	Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 1054-61	3.9	27
148	Pain treatment of agitation in patients with dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 1012-8	3.9	70
147	The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD). <i>International Journal of Palliative Nursing</i> , 2011 , 17, 420, 422, 424	0.9	26
146	Early and presenting symptoms of dementia with lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 202-8	2.6	62
145	CSF amyloid B8 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 160-4	5.5	38
144	Depressive symptoms in Alzheimer's disease and lewy body dementia: a one-year follow-up study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 143-9	2.6	38
143	Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 35-43	4.1	95
142	Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. <i>Acta Neurologica Scandinavica</i> , 2010 , 122, 418-24	3.8	43
141	The epidemiology of dementia associated with Parkinson's disease. <i>Brain Pathology</i> , 2010 , 20, 633-9	6	181
140	Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 510-5	2.6	20
139	Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. <i>American Journal of Alzheimer& Disease and Other Dementias</i> , 2010 , 25, 407-13	2.5	17
138	CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1080-6	5.5	151
137	Core and suggestive symptoms of dementia with lewy bodies cluster in persons with mild dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 317-24	2.6	18
136	A 12-year population-based study of psychosis in Parkinson disease. <i>Archives of Neurology</i> , 2010 , 67, 996-1001		246
135	Is physical activity a potential preventive factor for vascular dementia? A systematic review. <i>Aging and Mental Health</i> , 2010 , 14, 386-95	3.5	131

(2009-2010)

134	alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010 , 22, 321-7	3.4	14
133	Biomarkers of PD progression: is CSF the answer?. <i>Neurology</i> , 2010 , 75, 1036-7	6.5	4
132	The epidemiology of dementia associated with Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2010 , 289, 18-22	3.2	276
131	Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 160-5	5.5	143
130	Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 725-31	3.9	32
129	Health and well-being in care staff and their relations to organizational and psychosocial factors, care staff and resident factors in nursing homes. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 789-97	3.9	45
128	Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. <i>Journal of Alzheimerg Disease</i> , 2010 , 20, 301-11	4.3	17
127	Rivastigmine for the treatment of Parkinson disease dementia. <i>Aging Health</i> , 2010 , 6, 277-284		
126	Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study. <i>Neurobiology of Aging</i> , 2010 , 31, 104-13	5.6	49
125	Apathy in drug-nalle patients with incident Parkinson's disease: the Norwegian ParkWest study. Journal of Neurology, 2010 , 257, 217-23	5.5	73
124	The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 1030-8	3.9	53
123	Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. <i>Movement Disorders</i> , 2010 , 25, 687-95	7	117
122	Gray matter correlations of cognition in incident Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 629	9 <i>-</i> j33	52
121	Frequency and correlates of caregiver-reported sleep disturbances in a sample of persons with early dementia. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 480-6	5.6	91
120	The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 80-6	4.6	59
119	Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. <i>International Psychogeriatrics</i> , 2009 , 21, 216-9	3.4	51
118	High prevalence of orthostatic hypotension in mild dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 28, 307-13	2.6	44
117	APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009 , 22, 166-70	3.8	42

116	Person-centred care and care mapping in dementia. Lancet Neurology, The, 2009, 8, 302-3	24.1	10
115	Neuropsychiatric symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 2175-86	7	376
114	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology, The</i> , 2009 , 8, 613-8	24.1	358
113	Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 295-9	3.6	108
112	The association between motor subtypes and psychopathology in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 379-82	3.6	150
111	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 8754-9	11.5	158
110	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. <i>NeuroImage</i> , 2009 , 47, 2083-9	7.9	54
109	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 385-93	27.4	758
108	Pain and its relationship to depression in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2009 , 17, 269-75	6.5	72
107	Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. <i>Alzheimer Disease and Associated Disorders</i> , 2009 , 23, 295-7	2.5	142
106	Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 445-52	2.6	145
105	Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 183-6	3.6	24
104	Grey matter atrophy in early versus late dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 620-5	3.6	16
103	Who suffers most? Dementia and pain in nursing home patients: a cross-sectional study. <i>Journal of the American Medical Directors Association</i> , 2008 , 9, 427-33	5.9	106
102	Clinical aspects of Parkinson dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 303-6	3	
101	Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 195-205	2.6	28
100	Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1084-90	5	31
99	Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 330-8	2.6	34

98	Dementia in Parkinson's disease. Current Opinion in Neurology, 2008, 21, 676-82	7.1	71
97	A systematic review of prevalence studies of depression in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 183-9; quiz 313	7	781
96	Scales to assess psychosis in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008 , 23, 484-500	7	143
95	Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled studythe Bergen District Nursing Home Study (BEDNURS). <i>International Journal of Geriatric Psychiatry</i> , 2008 , 23, 889-95	3.9	60
94	Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 559-63	2.6	40
93	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1581-7	2.9	61
92	Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. <i>Neurology</i> , 2007 , 69, 747-54	6.5	135
91	Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1097-102	5.5	109
90	Subthreshold depression in patients with Parkinson's disease and dementiaclinical and demographic correlates. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 980-5	3.9	14
89	Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. <i>Movement Disorders</i> , 2007 , 22, 1061-8	7	371
88	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1689-707; quiz 1837	7	1968
87	Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007 , 22, 2314-24	7	708
86	Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. <i>Neuropathology and Applied Neurobiology</i> , 2007 , 33, 586-90	5.2	10
85	The effect of age of onset of PD on risk of dementia. <i>Journal of Neurology</i> , 2007 , 254, 38-45	5.5	118
84	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 254-9	5.5	202
83	Are anxiety disorders undertreated in patients with multiple sclerosis?. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 372-3		6
82	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1064-8	5.5	68
81	FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007 , 20, 89-92	3.8	28

80	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. <i>Neurobiology of Disease</i> , 2006 , 23, 481-9	7.5	99
79	Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2006 , 21, 252-8	3.9	74
78	Visual rating of white matter hyperintensities in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 223	3- 9	84
77	Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. <i>Movement Disorders</i> , 2006 , 21, 337-42	7	87
76	Changes in motor subtype and risk for incident dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1123-30	7	320
75	Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. <i>Movement Disorders</i> , 2006 , 21, 1343-9	7	471
74	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1899-907	7	236
73	Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study. <i>Movement Disorders</i> , 2006 , 21, 2170-4	7	19
72	Familial occurrence of dementia and parkinsonism: a systematic review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 22, 288-95	2.6	19
71	Current perspectives in dementia with Lewy bodies. <i>Aging Health</i> , 2006 , 2, 461-472		1
70	Management of Parkinson's disease dementia: practical considerations. <i>Drugs and Aging</i> , 2006 , 23, 807	- 2 427	16
69	Rivastigmine in Parkinson Disease Dementia. CNS Drugs, 2006, 20, 748-750	6.7	1
68	Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006 , 27, 433-8	5.6	56
67	Psychiatric aspects of Parkinson's disease. <i>Current Opinion in Psychiatry</i> , 2005 , 18, 335-41	4.9	10
66	The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2005 , 112, 386-90	3.8	49
65	Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005 , 112, 201-7	6.5	60
64	Neuropsychiatric symptoms in patients with multiple sclerosis. <i>Acta Psychiatrica Scandinavica</i> , 2005 , 112, 463-8	6.5	78
63	The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2005 , 20, 587-90	3.9	87

(2004-2005)

62	Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. <i>Annals of Neurology</i> , 2005 , 58, 773-6	9.4	280
61	A systematic review of prevalence studies of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 1255-63	7	636
60	Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management. <i>Current Neurology and Neuroscience Reports</i> , 2005 , 5, 345-54	6.6	15
59	Role of Neuropsychiatric Assessment in Diagnosis and Research 2005 , 163-183		
58	Progression of motor impairment and disability in Parkinson disease: a population-based study. <i>Neurology</i> , 2005 , 65, 1436-41	6.5	196
57	Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005 , 18, 149-54	3.8	130
56	Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 504-514	4.6	128
55	Cognitive impairment and dementia in Parkinson's disease 2005 , 657-663		
54	Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 633-7	4.6	57
53	Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. <i>Advances in Neurology</i> , 2005 , 96, 56-64		18
52	Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 164-71	3.8	117
51	Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. <i>Archives of Neurology</i> , 2004 , 61, 919-25		274
50	Psychiatric Aspects of Parkinson Disease, Parkinson Disease with Dementia, and Dementia with Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 111-111	3.8	0
49	Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 137-45	3.8	156
48	Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia. <i>Psychiatry and Clinical Neurosciences</i> , 2004 , 58, 343-7	6.2	66
47	Dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2004 , 3, 19-28	24.1	560
46	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004 , 3, 397-412		3
45	A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 58-67	3.9	87

44	Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 371-7	3.9	101
43	Psychiatric issues in non-Alzheimer dementias. Clinical Neuroscience Research, 2004, 3, 397-397		O
42	Rivastigmine for dementia associated with Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2509-18	59.2	919
41	The rate of cognitive decline in Parkinson disease. <i>Archives of Neurology</i> , 2004 , 61, 1906-11		181
40	Basal ganglia diseases and geriatric psychiatry: a new approach. <i>Current Opinion in Psychiatry</i> , 2003 , 16, 621-627	4.9	
39	Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2003 , 18, 937-41	3.9	153
38	Familial Parkinson's disease: a community-based study. European Journal of Neurology, 2003, 10, 159-6	3 6	22
37	Neuropsychological profile of patients with Parkinson's disease without dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 15, 126-31	2.6	142
36	Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. <i>Archives of Neurology</i> , 2003 , 60, 387-92		1081
35	The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 78-84	3.9	173
34	Depression in Parkinson's disease. Acta Psychiatrica Scandinavica, 2002, 106, 161-2	6.5	11
33	Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 374-9	2.7	51
32	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 528-36	3.9	266
31	Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 184-91	3.9	122
30	Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 42-9	2.7	104
29	Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. <i>Journal of the American Geriatrics Society</i> , 2000 , 48, 938-42	5.6	517
28	Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. <i>Archives of Neurology</i> , 1999 , 56, 595-601		313
27	Neuropsychiatric aspects of Parkinson's disease. <i>Current Psychiatry Reports</i> , 1999 , 1, 61-8	9.1	48

26	Donepezil for dementia with Lewy bodies: a case study 1999 , 14, 69-72	48
25	Lexical and nonlexical spelling deficits in dementia of the Alzheimer type. <i>Brain and Language</i> , 1996 , 52, 551-63	16
24	Overview of Parkinson's disease: epidemiology, diagnosis, course, medical and surgical management1-13	
23	Parkinson∃ disease: pathology, anatomy, and behavior14-24	
22	The boundaries of Parkinson disease dementia and dementia with Lewy bodies 40-52	
21	Cognitive assessment in Parkinson disease 53-64	
20	Clinical assessment: mood and motivation65-72	
19	Imaging and behavior in Parkinson⊠ disease: structural imaging73-88	
18	Imaging and behavior in Parkinson⊠ disease: functional imaging89-96	
17	Diagnosis and biomarkers: CSF97-108	
16	Apathy131-139	
15	Impulse control disorders and related behaviors140-152	2
14	Psychosis153-162	
13	Early cognitive impairment163-176	
12	Parkinson\ disease dementia177-191	
11	Sleep disturbances192-210	
10	Surgical treatment and behavior230-243	
9	Clinical trials for psychotropic agents in Parkinson's disease using psychosis as a model244-254	

7	Neuropsychiatric and cognitive disorders in other parkinsonian disorders261-274	2
6	Neuropsychiatric aspects of the on/off phenomenon275-284	
5	Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies285-291	
4	The genetics of behavior and cognition in Parkinson disease 25-39	
3	Man with fluctuating confusion148-154	
2	Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimer∄ disease risk	12
1	Plasma Neurofilament Light Chain predicts cognitive progression in prodromal and clinical dementia with Lewy Bodies	1

The impact of neuropsychiatric symptoms on quality of life in Parkinson's disease255-260

8